title: Tiagabine.
authors.affiliation: Abbott Laboratories, Abbott Park, IL.
authors.forename: M W
authors.initials: MW
authors.lastname: Pierce
authors.forename: P D
authors.initials: PD
authors.lastname: Suzdak
authors.forename: L E
authors.initials: LE
authors.lastname: Gustavson
authors.forename: H B
authors.initials: HB
authors.lastname: Mengel
authors.forename: J F
authors.initials: JF
authors.lastname: McKelvy
authors.forename: T
authors.initials: T
authors.lastname: Mant
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005071:Evoked Potentials / Q000187:drug effects; D006801:Humans; D051379:Mice; D009557:Nipecotic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D000078308:Tiagabine
chemical_list: D000927:Anticonvulsants; D015507:Drugs, Investigational; D009557:Nipecotic Acids; D000078308:Tiagabine